Bioinformatics analysis identifies AURKB as a prognostic biomarker across multiple human cancers
AURKB is a significant prognostic biomarker and potential therapeutic target, with overexpression linked to poor outcomes and chemotherapy resistance. The association with hypomethylation suggests an epigenetic role, supporting targeted therapies. AURKB's influence on immune suppression highlights its role in the tumor microenvironment. Clinical integration of AURKB analysis could enhance personalized treatment, and future research should explore combination therapies with AURKB inhibitors.
Authors
- Zhenyang Fu (ORCID: https://orcid.org/0000-0002-8081-2484)
- Meiqiang Xie
- He Li (ORCID: https://orcid.org/0009-0003-9885-1865)
- Yuexun Huang (ORCID: https://orcid.org/0009-0004-0788-8142)
- haolin wen
- Sicheng Chen
- Haomin Xie
- Wentao Zheng
- Aibing Wu
Institutions
- Macau University of Science and Technology (MO)
- Sun Yat-sen University (CN)
- Guangdong Pharmaceutical University (CN)
- University of Macau (MO)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Shanxi Province Hospital of Traditional Chinese Medicine (CN)
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
- Shantou Central Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1007/s12672-025-04105-7
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00